Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)
Fineberg N.A., Hollander E., Grant J.E., Chamberlain S.R., Drummond L.M., Pellegrini L., et al. (2022). Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1). COMPREHENSIVE PSYCHIATRY, 116, 152323-152332 [10.1016/j.comppsych.2022.152323].
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)
Pellegrini L.;
2022
Abstract
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
